-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On October 11, Kaifeng Pharmaceutical announced that the clinical trial of ALK-1 monoclonal antibody (GT90001C) combined with Nivolumab has been approved by the China National Medical Products Administration on October 9 for use in advanced hepatocytes without systemic treatment.
Cancer (HCC) patients
.
ALK-1 monoclonal antibody is a fully human monoclonal antibody that can inhibit ALK-1/TGF-β signal transduction and tumor angiogenesis.
It is a potential first-in-class anti-angiogenesis inhibitor
.
The company obtained the exclusive global development, production and commercialization rights of the drug from Pfizer in 2018
The Phase II clinical trial (NCT03893695) of ALK-1 monoclonal antibody combined with Nivolumab for advanced HCC patients who progressed after treatment with rafenib or lenvatinib was first launched in Taiwan, China on May 7, 2019
.
On January 17, 2021, the positive data of the Taiwanese clinical trial announced by the company at the 2021 American Society of Clinical Oncology Gastrointestinal Tumor Symposium (ASCO GI 2021) showed that the efficacy of the combination therapy is encouraging and the safety is good.
On February 11, 2021, the Phase II clinical trial of ALK-1 monoclonal antibody combined with Nivolumab for the treatment of HCC was approved by the US FDA